Durvalumab plus tremelimumab for advanced hepatocellular carcinoma is associated with a neutrophil/lymphocyte ratio

被引：0
|
作者：
Sugimoto, Rie [1 ]
Senjyuu, Takeshi [2 ]
Aratake, Yoshifusa [3 ]
Kuwano, Akifumi [4 ]
Ueda, Akihiro [5 ]
Nakamura, Tsukasa [6 ]
Goya, Takeshi [7 ]
Morita, Yuusuke [1 ]
Tanaka, Yuki [1 ]
Kojima, Motoyuki [3 ]
Tanaka, Masatake [7 ]
机构：
[1] NHO Kyushu Canc Ctr, Dept Hepatobiliary Pancreatol, Fukuoka, Japan
[2] Kyushu Rosai Hosp, Kitakyushu, Fukuoka, Japan
[3] NHO Kyusyu Med Ctr, Fukuoka, Japan
[4] Iizuka Hosp, Iizuka, Fukuoka, Japan
[5] Saiseikai Fukuoka Gen Hosp, Fukuoka, Japan
[6] Fukuoka City Hosp, Fukuoka, Japan
[7] Kyushu Univ, Dept Med & Bioregulatory Sience, Fukuoka, Japan
来源：
CANCER SCIENCE | 2025年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-2184
引用
收藏
页码：963 / 963
页数：1
相关论文
共 50 条
  • [11] Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab
    Myojin, Yuta
    Babaei, Sepideh
    Trehan, Rajiv
    Hoffman, Christoph
    Kedei, Noemi
    Ruf, Benjamin
    Benmebarek, Mohamed-Reda
    Bauer, Kylynda C.
    Huang, Patrick
    Ma, Chi
    Monge, Cecilia
    Xie, Changqing
    Hrones, Donna
    Duffy, Austin G.
    Armstrong, Paul
    Kocheise, Lorenz
    Desmond, Fiona
    Buchalter, Jemma
    Galligan, Marie
    Cantwell, Colin
    Ryan, Ronan
    Mccann, Jeff
    Bourke, Michele
    Mac Nicholas, Ross
    Mcdermott, Ray
    Awosika, Joy
    Cam, Maggie
    Krebs, Rosanna
    Budhu, Anuradha
    Revsine, Mahler
    Figg, William D.
    Kleiner, David E.
    Redd, Bernadette
    Wood, Bradford J.
    Wang, Xin Wei
    Korangy, Firouzeh
    Claassen, Manfred
    Greten, Tim F.
    GUT, 2025,
  • [12] WNT/β-catenin Signaling and CD8+Tumor-infiltrating Lymphocytes in Tremelimumab Plus Durvalumab for Advanced Hepatocellular Carcinoma
    Kuwano, Akifumi
    Tanaka, Kosuke
    Takahira, Junro
    Suzuki, Hideo
    Ohishi, Yoshihiro
    Motomura, Kenta
    IN VIVO, 2024, 38 (06): : 2774 - 2781
  • [13] Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma
    Chamseddine, Shadi
    Lapelusa, Michael
    Xiao, Lianchun
    Mohamed, Yehia, I
    Lee, Sunyoung S.
    Hu, Zishuo Ian
    Hatia, Rikita, I
    Hassan, Manal
    Yao, James C.
    Duda, Dan G.
    Datar, Saumil
    Amin, Hesham M.
    Kaseb, Ahmed
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 455 - 461
  • [14] Higher neutrophil-lymphocyte ratio is associated with better prognosis of hepatocellular carcinoma
    Li, Sheng-chao
    Xu, Zhuo
    Deng, Yan-li
    Wang, Ya-ni
    Jia, Yu-ming
    MEDICINE, 2020, 99 (27) : E20919
  • [15] Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
    Ishihara, Nobuaki
    Komatsu, Shohei
    Yano, Yoshihiko
    Fujishima, Yoshimi
    Ishida, Jun
    Kido, Masahiro
    Gon, Hidetoshi
    Fukushima, Kenji
    Urade, Takeshi
    Yoshida, Toshihiko
    Tai, Kentaro
    Arai, Keisuke
    Yanagimoto, Hiroaki
    Toyama, Hirochika
    Matsuura, Takanori
    Tada, Toshifumi
    Kodama, Yuzo
    Fukumoto, Takumi
    ANTICANCER RESEARCH, 2025, 45 (01) : 251 - 260
  • [16] Neutrophil-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma
    Li, Xing
    Chen, Zhan-Hong
    Ma, Xiao-Kun
    Chen, Jie
    Wu, Dong-Hao
    Lin, Qu
    Dong, Min
    Wei, Li
    Wang, Tian-Tian
    Ruan, Dan-Yun
    Lin, Ze-Xiao
    Xing, Yan-Fang
    Deng, Yun
    Wu, Xiang-Yuan
    Wen, Jin-Yun
    TUMOR BIOLOGY, 2014, 35 (11) : 11057 - 11063
  • [17] Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice
    Hiraoka, Atsushi
    Tada, Toshifumi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ohama, Hideko
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Kawata, Kazuhito
    Naganuma, Atsushi
    Kosaka, Hisashi
    Matono, Tomomitsu
    Kuroda, Hidekatsu
    Yata, Yutaka
    Nishikawa, Hiroki
    Imai, Michitaka
    Aoki, Tomoko
    Ochi, Hironori
    Tada, Fujimasa
    Nakamura, Shinichiro
    Nakamura, Yoshiko
    Nouso, Kazuhiro
    Morishita, Asahiro
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Tsutsui, Akemi
    Nagano, Takuya
    Tanaka, Kazunari
    Tanaka, Hironori
    Koshiyama, Yuichi
    Kanayama, Yuki
    Noritake, Hidenao
    Enomoto, Hirayuki
    Kaibori, Masaki
    Hiasa, Yoichi
    Kudo, Masatoshi
    Kumada, Takashi
    HEPATOLOGY RESEARCH, 2025, 55 (03) : 444 - 453
  • [18] Durvalumab and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
    Ryan, Carrie E.
    Lambdin, Jacob
    Shah, Shimul
    Quillin, Ralph Cutler
    Lemon, Kristina
    Hernandez, Jonathan M.
    Sohal, Davendra
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (02) : 686 - 687
  • [19] Myositis and myocarditis with tremelimumab and durvalumab combination therapy for hepatocellular carcinoma
    Lopez, Thais Lizondo
    Mendez, Iria Carro
    Martin, Esther Carcelero San
    MEDICINA CLINICA, 2024, 162 (07): : 358 - 359
  • [20] Durvalumab and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
    Carrie E. Ryan
    Jacob Lambdin
    Shimul Shah
    Ralph Cutler Quillin
    Kristina Lemon
    Jonathan M. Hernandez
    Davendra Sohal
    Annals of Surgical Oncology, 2023, 30 : 686 - 687
12345